Hosni assumed his current position in 2021. The Saudi-based pharmaceutical company reported $400 million in revenues and serves 37 countries across nine therapeutic areas in 2025. In Q1 2026, it reported $128 million in revenue and $562.7 million in assets. In 2025, Jamjoom Pharma signed 16 strategic agreements, including a landmark partnership with Lifera, a PIF company, to develop biologics, vaccines, and biosimilars in Saudi Arabia. The company launched six new products, bringing its portfolio to 147, and acquired Pfizer’s manufacturing facility in Saudi Arabia. Hosni previously held leadership roles at Pfizer and GSK.